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Abstract
Objectives To quantify the diagnostic accuracy of selected inflammatory
markers in addition to symptoms and signs for predicting pneumonia
and to derive a diagnostic tool.
DesignDiagnostic study performed between 2007 and 2010. Participants
had their history taken, underwent physical examination and
measurement of C reactive protein (CRP) and procalcitonin in venous
blood on the day they first consulted, and underwent chest radiography
within seven days.
Setting Primary care centres in 12 European countries.
Participants Adults presenting with acute cough.
Main outcome measures Pneumonia as determined by radiologists,
who were blind to all other information when they judged chest
radiographs.
ResultsOf 3106 eligible patients, 286 were excluded because of missing
or inadequate chest radiographs, leaving 2820 patients (mean age 50,
40% men) of whom 140 (5%) had pneumonia. Re-assessment of a
subset of 1675 chest radiographs showed agreement in 94% (κ 0.45,
95% confidence interval 0.36 to 0.54). Six published “symptoms and
signsmodels” varied in their discrimination (area under receiver operating
characteristics curve (ROC) ranged from 0.55 (95% confidence interval
0.50 to 0.61) to 0.71 (0.66 to 0.76)). The optimal combination of clinical
prediction items derived from our patients included absence of runny
nose and presence of breathlessness, crackles and diminished breath
sounds on auscultation, tachycardia, and fever, with an ROC area of
0.70 (0.65 to 0.75). Addition of CRP at the optimal cut off of >30 mg/L
increased the ROC area to 0.77 (0.73 to 0.81) and improved the
diagnostic classification (net reclassification improvement 28%). In the
1556 patients classified according to symptoms, signs, and CRP >30
mg/L as “low risk” (<2.5%) for pneumonia, the prevalence of pneumonia
was 2%. In the 132 patients classified as “high risk” (>20%), the
prevalence of pneumonia was 31%. The positive likelihood ratio of low,
intermediate, and high risk for pneumonia was 0.4, 1.2, and 8.6
respectively. Measurement of procalcitonin added no relevant additional
diagnostic information. A simplified diagnostic score based on symptoms,
signs, and CRP >30 mg/L resulted in proportions of pneumonia of 0.7%,
3.8%, and 18.2% in the low, intermediate, and high risk group
respectively.
Conclusions A clinical rule based on symptoms and signs to predict
pneumonia in patients presenting to primary care with acute cough
performed best in patients with mild or severe clinical presentation.
Correspondence to: B D L Broekhuizen b.d.l.broekhuizen@umcutrecht.nl
Extra material supplied by the author (see http://www.bmj.com/content/346/bmj.f2450?tab=related#webextra)
Appendix 1: Standard operating procedure for assessment and feedback of chest radiographs
Appendix 2: Characteristics of included patients with radiography available
Appendix 3: Calibration plots of validation models, new developed “symptoms and signs” model and “symptoms and signs model + CRP”
Appendix 4: Reclassification tables comparing diagnostic risk categories of pneumonia by diagnostic models with and without CRP
Appendix 5: Nomogram relating diagnostic items of final model to probability of pneumonia
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2013;346:f2450 doi: 10.1136/bmj.f2450 (Published 30 April 2013) Page 1 of 12
Research
RESEARCH
Addition of CRP concentration at the optimal cut off of >30mg/L improved
diagnostic information, but measurement of procalcitonin concentration
did not add clinically relevant information in this group.
Introduction
Diagnosis of pneumonia in adults presenting with signs of lower
respiratory tract infection in primary care is important because
pneumonia requires specific treatment and follow-up, whereas
for acute bronchitis expectant management is usually
appropriate.1
Nonetheless, accurate diagnosis of pneumonia in primary care
is difficult as it is not feasible to obtain chest radiographs in all
patients with lower respiratory tract infection. Primary care
physicians therefore have to rely on signs and symptoms and
simple additional tests, when available. Several studies, mostly
conducted in secondary care, have assessed the diagnostic value
of history and findings on physical examination for
pneumonia.2-12 These diagnostic models have been validated
only once in primary care.13 The number of patients included
in that validation study was small overall, but the prevalence
of pneumonia was three times higher than the 6% prevalence
that is usually reported in primary care.14
Regarding markers of inflammation, recent reviews found that
C reactive protein (CRP) had limited diagnostic value for
pneumonia in primary care when the probability of pneumonia
is below 10%.15 16 Studies included in this review, however,
came from various settings, and the studies from primary care
were small. Furthermore, the diagnostic value of another
potentially important biomarker, procalcitonin,17 has never been
assessed in addition to history and clinical examination in
primary care patients with lower respiratory tract infection.
We therefore studied a large group of primary care patients
presenting with signs of lower respiratory tract infection, firstly,
to validate published diagnostic models for pneumonia and,
secondly, to quantify whether CRP and procalcitonin
concentrations add information to history and physical
examination, and whether these could be combined in a
clinically useful diagnostic tool.
Methods
This cross sectional observational study used data from the
GRACE-09 study (Genomics to combat Resistance against
Antibiotics in Community-acquired LRTI in Europe; www.
grace-lrti.org), which collected data from patients presenting
with acute cough in 16 primary care networks in 12 European
countries. Participating general practitioners recruited eligible
patients from October 2007 to April 2010. A total of 3106
patients were included in the GRACE study.
Data analysis
Less than 0.1% of history items, 1% of physical examination
items, and 5% blood test data were missing (table 1⇓). Data are
rarely missing completely at random, and we therefore
performed multivariate imputation by chained equations.21-23
Missing results were imputed for all variables evaluated for the
diagnostic model but not for “pneumonia,” as we analysed only
participants for whom this diagnostic outcome was known. To
impute missing results, we used results of all variables in table
1⇓.
Recruiting health professionals were asked to keep logs of
patients whowere eligible but not recruited and to record reasons
for not screening patients at the end of the study. Clinical
characteristics of non-recruited patients were compared with a
recent observational study24 that used the same case definition
and case record form.We identified published diagnostic models
for pneumonia2-9 11 12 by selecting references from an existing
validation study13; searching PubMed from 2003 to 2012,
supplemented by checking article references; and selecting
references from the recently updated guidelines from the
European Respiratory Society for management of adults with
lower respiratory tract infection.25 We excluded studies that did
not report a multivariable model4 8 11 or regression coefficients
of the diagnostic variables3 or that used diagnostic tests that are
not readily available in European primary care (such as leucocyte
count5 and pulse oximetry8 11). For the remaining models2 6 7 9 12
we computed the probability of pneumonia for all our 2820
study patients and calculated the area under the receiver
operating characteristic curve with 95% confidence intervals.
Calibration of the models was graphically assessed with
calibration plots26 and tested with the Hosmer-Lemeshow
statistic.
As we expected existing models to perform suboptimally in our
external validation study, as previously found,13 we determined
from our data which items from history and physical
examination independently contributed to the discrimination
between presence and absence of pneumonia and whether the
diagnostic accuracy of history taking and physical examination
could be improved by blood tests. Accordingly, and given the
total number of cases of pneumonia in our study (n=140), we
preselected a set of 14 candidate diagnostic items that were most
promising based on published literature.2-13 27We then calculated
univariate odds ratios and 95% confidence intervals for each
candidate diagnostic variable with the outcome, using logistic
regression modelling. For continuous variables (age, CRP,
procalcitonin), we used visual inspection to assess whether the
inclusion of a non-linear component showed a clear deviation
from a linear association in a graph.26No deviation from linearity
was found.
As in most multicentre studies, individual patient data were
likely to be clustered within the 12 different countries, which
could affect the association of the diagnostic variables with the
outcome. We accounted for such possible non-random
differences within countries (clusters) using multilevel logistic
regression techniques.We used a random effect for the intercept
(to adjust for differences in baseline prevalence of pneumonia
per cluster) as well as for each candidate variable (to adjust for
differences in the associations between variable and outcome
per cluster).28-31 After we rounded the results, this multilevel
analysis identified the same intercept, odds ratios (associations),
and confidence intervals as the standard multivariable logistic
regression analysis, and therefore we used results from the latter
for all further analysis. All 14 preselected diagnostic predictors
from history taking and physical examination were entered in
a multivariable logistic regression model. We explicitly did not
select items based on univariate results as this often leads to
unstable models.32 33 With backward selection, with P<0.10 for
the likelihood ratio test, we fitted a reduced diagnostic
“symptoms and signs” model and computed the ROC area and
calibration plot.26 34
We repeated regression analyses after adding CRP and
procalcitonin concentrations as continuous offset variables,
while regression coefficients of symptoms and signs were
unchanged (“fixed”) using results from all patients. We used
the areas under the curve to quantify the added value of CRP
and procalcitonin beyond the “symptoms and signs” model. We
also analysed results for CRP and procalcitonin at clinically
relevant thresholds: >20, >30, >50, and >100mg/L for CRP7 8 35
and >0.25 µg/L and >0.50 µg/L for procalcitonin.36
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As physicians usually use dichotomised test results (normal v
abnormal) we also determined the additional benefit of CRP
and procalcitonin when used in this way, if continuous results
showed relevant added information. The most optimal cut-off
level was assessed from the area under the curve (that is, the
best trade off between sensitivity and specificity). The number
of patients correctly reclassified after the addition of CRP or
procalcitonin results to the diagnostic model was expressed in
the net reclassification improvement,37 with three predefined
diagnostic risk groups: low (probability <2.5%), intermediate
(2.5-20%), and high (>20%). This approach was chosen as this
is how we anticipate CRP would be used in practice—that is,
defining high, low, and intermediate risk groups based on
symptoms and signs then assessing the added value of CRP
based on the initial symptoms and signs model. We calculated
negative and positive predictive value, sensitivity, and specificity
for these three risk groups (taking one risk group compared with
the other two combined), as well as and positive and negative
likelihood ratios. The cut-off levels of the three risk groups were
based on clinical judgment of the authors and assessment of
acceptability of false negative results in other diagnostic studies
in primary care.38-41We carried out a sensitivity analysis around
these thresholds using low thresholds of 1% and 2% and high
thresholds of 15% and 25%.
Because any developed model can be over-fitted, we used
bootstrapping for internal validation. In 100 bootstrap samples
we repeated the analyses and, by evaluating the diagnostic model
performance in the bootstrap samples and in the original data,
obtained a shrinkage factor to adjust regression coefficients and
areas under the curve for overoptimism.42 To make a simple
tool for clinical practice, we also derived a simplified score from
the regression model of symptoms signs and CRP by rounding
all regression coefficients to 1 point.
Data were analysed with SPSS (version 17.0 for Windows) and
R (version 2.11.1) including the “RMS” package by Harrell for
R.43
Results
Patients’ characteristics
During three winters (October to April) from 2007 to 2010, 294
general practitioners initially recruited 3106 adult patients.
Recruitment of each participant and baseline assessments took
about half an hour. Hence, in the busiest periods, time pressures
resulted in only a portion of the potentially eligible patients
being screened and limited completion of non-recruitment logs.
The main reason reported by general practitioners for not
screening was “lack of time” (rated first by 44/48, 92%), with
only three (6%) reporting that individual clinical considerations
limited recruitment. The population had similar clinical
characteristics to the previous observational cohort recruited in
these primary care networks24 and other cohorts with lower
respiratory tract infection in primary care7 14: the mean age of
patients was 50 (SD 17) and 40% were men (table 1 ⇓). A
follow-up of 28 days showed no mortality, and 11 patients
(0.5%) were admitted to hospital. Patients who were excluded
because radiography was not performed (n=258) or was of
insufficient quality (n=28) (fig 1⇓) were no different, apart from
age (see appendix 2).
Prevalence of pneumonia
Of the 2820 participants, 140 had pneumonia (5%). After
reassessment, the diagnosis of presence or absence of pneumonia
was concordant in 1571 of 1675 patients (94%). The positive
agreement (49%) was much lower than negative agreement
(97%). Cohen’s unweighted κ was 0.45 (moderate agreement)
(95% confidence interval 0.36 to 0.54). Other diagnoses on
chest radiography were “acute bronchitis” in 217 patients (8%)
and “other diagnosis” in 462 patients (16%), of which chronic
bronchitis/emphysema, cardiomegaly, atelectasis, fibrotic
changes (such as old tuberculosis), and aortic changes were
most commonly reported. The chest radiograph was reported
as normal for 2023 (72%) patients. Most (2555, 91%)) patients
underwent chest radiography within five days, and the mean
duration between the first consultation for acute cough and chest
radiography was 1.6 days (SD 2.6). There was no correlation
between the time until radiography and presence of radiographic
pneumonia (P=0.63).
Validation of existing diagnostic models
In our population the area under the curve for previously
published models of signs and symptom for pneumonia varied
between 0.55 and 0.68 (up to 0.71 after addition of CRP) (table
2⇓). All models showed poor calibration for pneumonia (see
appendix 3), with a Hosmer-Lemeshow of P<0.001, indicating
poor fit.
Diagnostic value of “symptoms and signs”
Items of history and physical examination with independent
diagnostic value were absence of runny nose and presence of
breathlessness, crackles and diminished breath sounds on
auscultation, tachycardia (>100/min), and fever (temperature
≥37.8°C) (table 1⇓). Combination of these items (“symptoms
and signs” model) resulted in an area under the curve of 0.70
(95% confidence interval 0.65 to 0.75), which remained the
same after internal validation. Calibration of this model was
good (see appendix 3) with a Hosmer-Lemeshow test of 7.35
(df=8, P=0.50).
Added information on CRP
The mean CRP concentration was 19 mg/L (SD 35 mg/L) and
69 mg/L (SD 83 mg/L) in patients with pneumonia, with a
univariate odds ratio of 1.2 (95% confidence interval 1.1 to 1.2)
per 10mg/L increase in concentration. CRP concentrations were
<20, 20-30, 30-50, 50-100, and >100 mg/L in 74%, 8%, 9%,
6%, and 3% of patients, respectively. The proportion with
pneumonia in these groups was 3%, 5%, 7%, 15%, and 35%
respectively. Positive predictive values of CRP as a univariate
(stand-alone) test were 11.8%, 14.8%, 22.5%, and 35.4% for
concentrations over 20, 30, 50, and 100 mg/L, respectively.
Negative predictive values were 97.4%, 97.2%, 96.8%, and
96.1%. Some 54 patients (3%) with radiographic pneumonia
had a CRP concentration <20 mg/L. Compared with the total
study population, these 54 patients were older (P=0.01), more
often used (inhaled or oral) steroids (P=0.04), and more often
had positive symptoms and signs of the clinical diagnostic model
(data not shown), but the duration of illness before consultation
did not differ (P=0.77).
Addition of continuous CRP concentration to the “symptoms
and signs” model resulted in a multivariable odds ratio for
pneumonia of 1.2 (95% confidence interval 1.1 to 1.2) per 10
mg/L rise in concentration and increased the area under the
curve significantly from 0.70 (0.65 to 0.75) to 0.78 (0.74 to
0.82) (P<0.05, fig 2⇓). Calibration of the model extended with
CRP was good (Hosmer-Lemeshow test 10.69, df=8, P=0.22;
see appendix 4). Addition of CRP as a dichotomised variable,
where 30 mg/L was the most optimal threshold, resulted in an
area under the curve of 0.77 (0.73 to 0.81) with a
Hosmer-Lemeshow test of 9.67 (df=8, P=0.29).
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Added information on procalcitonin
The mean procalcitonin concentration was 0.09 µg/L (SD 0.6
µg/L) overall and 0.38 µg/L (SD 2.6 µg/L) in patients with
pneumonia, with a univariate odds ratio of 1.3 (95% confidence
interval 1.2 to 1.4) per 0.1 µg/L increase in concentration.
Procalcitonin concentrations were ≤0.25, 0.25-0.50, and >0.50
µg/L in 94%, 3%, and 3% of patients, respectively. The
proportion of pneumonia in these groups was 5%, 7%, and 18%,
respectively. Addition of continuous procalcitonin to the
“symptoms and signs” model resulted in a multivariable odds
ratio for pneumonia of 1.1 (95% confidence interval 1.1 to 1.2)
per 0.1 µg/L rise in concentration and increased the area under
the curve to 0.72 (0.68 to 0.77; P>0.05) and 0.71 (0.67 to 0.76)
after internal validation (fig 2⇓). Calibration of the model
extended with procalcitonin was good (Hosmer-Lemeshow test
7.56, df=8, P=0.48).
Because of the limited added value of continuous procalcitonin
results, it was not further analysed.
Diagnostic risk classification
Table 3⇓ shows the diagnostic risk classification by the model
with and without CRP. Based on symptoms and signs only, in
the 665 patients with a low (<2.5%) estimated probability of
pneumonia, 11 (2%) actually had pneumonia (positive likelihood
ratio 0.3, negative likelihood ratio 1.2, negative predictive value
98%, sensitivity 8%, specificity 76%). In the 63 patients with
a high (>20%) estimated probability, 24 actually had pneumonia
(positive likelihood ratio 11.8, negative likelihood ratio 0.8,
positive predictive value 38%, sensitivity 17%, specificity 99%).
The positive likelihood ratio of an intermediate diagnostic risk,
which included most patients, was 1.01 and the negative
likelihood ratio was 0.97. Addition of CRP increased the number
of patients with estimated low risk to 1556 (31, 2%) had
pneumonia, positive likelihood ratio 0.4, negative likelihood
ratio 1.8, negative predictive value 98%, sensitivity 22%,
specificity 43%) and the number of patients with estimated high
risk to 132 (41, 31%) had pneumonia, positive likelihood ratio
8.6, negative likelihood ratio 0.7, positive predictive value 31%,
sensitivity 29%, specificity 97%). In the intermediate risk class
the positive and negative likelihood ratios were 1.2 and 0.9,
respectively. In 1640 patients (58%), addition of CRP did not
change the estimated risk class. The net reclassification
improvement was 28% (95% confidence interval 17% to 30%).
A threshold of 2% and 1% for low probability resulted in a net
reclassification improvement of 26% (16% to 36%) and 10%
(4% to 27%), respectively. With 15% and 25% as a threshold
for high probability, the net reclassification improvement was
24% (14% to 34%) and 26% (16% to 3%5), respectively (see
appendix 4). Re-analysis with presence of pneumonia according
to the (secondly) centrally read radiographs as the reference test
showed a net reclassification improvement of 28% (19% to
37%).
CRP in intermediate risk group
Most reclassifications of diagnostic risk considered patients
with intermediate risk based on symptoms and signs. Of the
1987 patients without pneumonia who were classified as
intermediate risk based on symptoms and signs, after addition
of CRP >30 mg/L 957 were reclassified (correctly) to low risk
and 64 were reclassified (incorrectly) to high risk. Of the 105
patients with pneumonia classified as intermediate risk, addition
of CRP reclassified 27 to low risk and 22 to high risk (table 3⇓).
Diagnostic classification by a simplified
diagnostic score
Rounding of all regression coefficients in the model including
symptoms signs and CRP >30 mg/L to 1 point resulted in the
simplified diagnostic score presented in table 4⇓. The
proportions of pneumonia were 0.7%, 4%, and 18%,
respectively, in the estimated low, intermediate, and high risk
class.
Because the simplified score in table 4 had a considerably lower
diagnostic accuracy than the model that used the results of the
original β coefficients, we developed a nomogram to enable
physicians to use the original β coefficients (see appendix 5).
The nomogram allows for calculation of the added value of CRP
in all patients but is mainly meant to enable targeted use of a
CRP test in patients at intermediate risk based on symptoms
and signs alone.
Discussion
Main findings
Pneumonia was diagnosed by chest x radiography in 140 (5%)
of the 2820 patients presenting to primary care with acute cough.
The optimal combination of symptoms and signs for predicting
pneumonia was absence of runny nose and presence of
breathlessness, crackles and diminished breath sounds on
auscultation, tachycardia, and fever. Signs and symptoms were
useful in correctly identifying patients with a “low” (<2.5%) or
“high” (>20%) diagnostic risk in 26% of patients. In the 74%
of patients in whom diagnostic doubt remained (estimated risk
2.5%-20%), measurement of C reactive protein (CRP)
concentration helped to correctly exclude pneumonia. A
simplified diagnostic score based on symptoms, signs, and CRP
concentration resulted in proportions of pneumonia of 0.7%,
4%, and 18% in the low, intermediate, and high risk group,
respectively. Measurement of procalcitonin concentration had
no clinically relevant added value in this setting.
Strengths and limitations
This is the first study to quantify the independent diagnostic
value of symptoms, signs, and additional diagnostic value of
inflammatory markers for pneumonia in patients presenting
with acute cough in primary care that included an adequate
number of cases of pneumonia. All blood samples were analysed
in the same laboratory with standardised procedures. Serum
CRP and procalcitonin concentrations were measured by
conventional venous blood tests in a diagnostic laboratory and
not with a point of care test. The added value of CRP might be
different and could be lower when measured with a point of
care test in general practice. Nonetheless, agreement between
point of care test results and a conventional reference test has
been shown to be good.44
Given how common lower respiratory tract infections are, many
more eligible patients presented during the recruitment period
than were approached about participation in this study, and
therefore we probably did not achieve the goals of recruiting
all consecutive, eligible patients. Nevertheless, we do not believe
that there was important clinical selection bias because feedback
from recruiting clinicians during and after the study was that
the time required to recruit and assess each patient made
sequential recruitment of every eligible patient impossible.
Chest radiographs were examined by local radiologists. We
attempted to increase uniformity in assessment by implementing
a protocol for reporting. While there was some variability
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between observers, the moderate unweighted κ of 0.45 was
similar to that reported in other studies.18 20
We did not attempt to distinguish between bacterial and viral
pneumonia as this is not feasible in routine primary care.14 45
All available relevant guidelines advocate identification of
patients with pneumonia and treatment with antibiotics without
further aetiological testing.14
Comparison with other studies
Absence of a runny nose and presence of dry cough,
breathlessness, chest pain, diarrhoea, fever, and crackles have
previously been found to have diagnostic value for pneumonia
in primary care populations.7 9 “Tachycardia” and “diminished
vesicular breathing” have diagnostic value in secondary care
populations.3 6 8 11 We were able to confirm the predictive value
of most of these items, apart from chest pain and diarrhoea.
Differences between our findings and those from previous
studies could relate to the difference in prevalence of pneumonia,
inclusion criteria, and outcome definition.
Our finding that CRP concentration can be low in people with
pneumonia is not new. Flanders and colleagues reported on a
small subgroup of patients with pneumonia who had a CRP of
less than 11 mg/L.3 In the 54 patients with pneumonia with low
CRP in our study, the estimated diagnostic risk of pneumonia
was high (n=3) or intermediate (n=51) based on history and
physical examination results as defined in our model. These
findings emphasise that CRP test results should be interpreted
together with clinical findings.
Of the factors known to lower CRP—such as steroid use46 and
duration of disease47—only steroid use (including both oral and
inhaled steroids) was significantly more prevalent in the group
of patients with pneumonia with low CRP concentration.
Exclusion of all steroid users from our analyses resulted in a
similar association between CRP concentration and pneumonia.
Procalcitonin concentrations in our study were higher in patients
with pneumonia and comparable with previous findings in
patients with lower respiratory tract infection in primary care.17 48
They did not, however, addmeaningful diagnostic information.
Holm and colleagues showed a clear association between
procalcitonin concentration and radiographic pneumonia as well
as bacterial infection,17 but the positive predictive value was too
low to be useful in clinical practice. Our findings support this
conclusion.Moreover, Holm and colleagues studied a population
with a higher prevalence of pneumonia (13%) and did not
combine history and physical examination with procalcitonin
test results.17
Implications for practice and conclusions
Although the diagnostic “symptoms and signs” model presented
in this study assigned an intermediate diagnostic risk of
pneumonia to most patients, history taking and physical
examination alone enabled general practitioners to correctly
identify a small group of patients at high risk. Chest radiography
and/or (empirical) antibiotic treatment should therefore be
considered in these patients. In these more severely ill patients,
point of care tests, including CRP, do not seem to be useful. In
patients with a low risk of pneumonia based on symptoms and
signs, it seems justified to withhold further diagnostic
investigation and not to treat with antibiotics.
CRP has additional diagnostic value in patients with an
intermediate diagnostic risk of pneumonia as determined by
symptoms and signs alone, especially in appropriately excluding
pneumonia. Procalcitonin has no additional diagnostic value in
primary care.
The simplified score derived from the regressionmodels is more
suitable for uptake in daily care than the regression models. The
downside of the simplified score is that it is less precise and
contains less diagnostic information. To determine whether our
diagnostic model improves clinical outcomes in everyday
practice would require an implementation study in which general
practitioners use point of care CRP testing with outcomes such
as patient recovery and the unnecessary prescription of
antibiotics. Further research should also determine the
performance of CRP in other settings where pneumonia is more
prevalent or where patients are more severely ill.
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What is already known on this topic
Studies have evaluated the diagnostic accuracy of signs and symptoms for pneumonia, but there is limited evidence applicable to primary
care
The added diagnostic value of C reactive protein (CRP) and procalcitonin concentrations to clinical signs and symptoms is unknown
What this study adds
Symptoms and signs (absence of runny nose and presence of breathlessness, crackles and diminished breath sounds on auscultation,
tachycardia, and fever) have moderate diagnostic accuracy for pneumonia in patients who present in primary care with acute cough
CRP concentration at the optimal threshold of >30 mg/L adds some diagnostic information by increasing diagnostic certainty in the
patients when doubt remains after history and physical examination
Procalcitonin concentration adds no clinically relevant information in primary care
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Tables
Table 1| Association between diagnostic variables and pneumonia in 2820 patients presenting with acute cough in primary care. Figures
are numbers (percentages) unless mentioned otherwise
P value
OR (95% CI)Pneumonia
present (n=140,
5%)Total (n=2820)MissingDiagnostic variable Multivariable*Univariable
History (day 1)
0.1181.1 (0.9 to 1.2)†1.1 (1.0 to 1.2)†54 (15)50 (17)0 (0.0)Mean (SD) age (years)
—NA1.2 (0.9 to 1.7)62 (44)1128 (40)0 (0.0)Men
—NA1.1 (0.8 to 1.5)64 (30)779 (28)2 (0.1)Current smoker
—NA1.0 (0.9 to 1.0)9 (6)10 (10)30 (1.1)Mean (SD) No of days’
illness before consultation
—NA0.1 (0.0 to 0.8)140 (100)2818 (100)2 (0.1)Cough
0.7241.1 (0.7 to 1.6)1.4 (1.0 to 2.0)56 (40)931 (33)0Severe cough
—NA1.6 (1.0 to 2.6)120 (86)2239 (79)2 (0.1)Phlegm
0.0251.4 (1.0 to 2.1)1.7 (1.2 to 2.5)96 (69)1594 (57)1 (0.0)Breathlessness
0.4191.3 (0.7 to 2.4)1.9 (1.1 to 3.4)17 (12)197 (7)0Severe breathlessness
<0.0011.9 (1.3 to 2.7)2.0 (1.4 to 2.8)61 (44)808 (29)1 (0.0)Runny nose absent
—NA2.8 (2.0 to 3.9)82 (59)989 (35)3 (0.1)Fever
0.4021.2 (0.8 to 1.7)1.6 (1.1 to 2.2)80 (57)1304 (46)3 (0.1)Chest pain
0.2241.5 (0.8 to 3.1)2.1 (1.2 to 4.0)13 (9)141 (5)0Severe chest pain
0.1651.5 (0.8 to 1.8)1.6 (0.9 to 1.8)15 (11)199 (7)2 (0.1)Diarrhoea
—NA1.3 (0.9 to 1.9)96 (69)1759 (62)1 (0.0)Interference with daily
activities
0.9601.0 (0.7 to 1.5)1.5 (1.1 to 2.2)50 (36)768 (27)4 (0.1)Any comorbidity (pulmonary,
cardiac, diabetes mellitus)‡
Physical examination (day 1)
0.7281.1 (0.7 to 1.6)1.3 (0.9 to 1.8)43 (31)739 (26)5 (0.2)General toxicity
0.0131.7 (1.1 to 2.6)2.0 (1.3 to 3.1)31 (22)362 (13)15 (0.5)Diminished vesicular
breathing
<0.0013.5 (2.3 to 5.2)5.3 (3.6 to 7.7)45 (32)265 (9)13 (0.5)Crackles
0.0032.3 (1.3 to 4.3)3.8 (2.2 to 6.6)17 (12)111 (4)36 (1.3)Tachycardia (pulse >100
beats/min)
0.4211.4 (0.9 to 2.0)2.4 (1.0 to 5.7)6 (4)55 (2)67 (2.4)Tachypnoea (>24
breaths/min)
—NA2.9 (1.4 to 5.9)9 (6)71 (3)58 (2.1)Blood pressure <90/60 mm
Hg
<0.0012.5 (1.4 to 4.4)3.5 (2.1 to 5.7)22 (16)158 (6)27 (1.0)Temperature >37.8°C
Blood test results (day 1)
CRP (mg/L):
<0.0011.1 (1.1 to 1.2)§1.2 (1.1 to 1.2)§69 (83)19 (35)142 (5.0)Mean (SD)
<0.0013.5 (2.4 to 5.0)4.9 (3.5 to 7.0)85 (61)726 (26)142 (5.0)>20
<0.0013.8 (2.7 to 5.5)5.9 (4.2 to 8.4)74 (53)501 (18)142 (5.0)>30
<0.0014.8 (3.2 to 7.1)8.9 (6.2 to 12.9)58 (41)255 (9)142 (5.0)>50
<0.0016.0 (3.6 to 10.0)13.5 (8.5 to 21.5)34 (24)96 (3)142 (5.0)>100
Procalcitonin (µg/L):
<0.0011.2 (1.1 to 1.3)¶1.2 (1.1 to 1.3)¶0.37 (2.6)0.09 (0.6)156 (5.5)Mean (SD)
<0.0012.2 (1.3 to 3.8)2.8 (1.7 to 4.6)20 (14)107 (6)156 (5.5)>0.25
<0.0013.2 (1.7 to 6.3)4.5 (2.5 to 8.3)14 (10)78 (3)156 (5.5)>0.50
NA=not analysed.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2013;346:f2450 doi: 10.1136/bmj.f2450 (Published 30 April 2013) Page 7 of 12
RESEARCH
Table 1 (continued)
P value
OR (95% CI)Pneumonia
present (n=140,
5%)Total (n=2820)MissingDiagnostic variable Multivariable*Univariable
*Variables entered in model, based on literature: age, breathlessness, runny nose, chest pain, diarrhoea, comorbidity (pulmonary, cardiac, or diabetes), general
toxicity, diminished vesicular breathing, crackles, tachycardia, tachypnoea, temperature >37.8°C. Both backward and forward selection showed same results.
ORs after internal validation are shown.
†Per 10 years.
‡Pulmonary comorbidity=history of asthma or COPD (chronic obstructive pulmonary disease). Cardiac comorbidity=history of heart failure or ischaemic heart
disease.
§Per 10 mg/L increase.
¶Per 0.10 µg/L increase.
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Table 2| Diagnostic value of publishedmodels to identify radiographic pneumonia in derivation (original) studies and in GRACE participants
Calibration‡
(P value)
Discrimination ROC area (95% CI)
Linear predictor
Pneumonia
prevalenceStudy
population
(setting*)
Validation in
GRACE
participantsValidation†
Derivation
study
(derivation
study)
7816 (<0.001)0.67 (0.62 to 0.72)——−2 for rhinorrhoea, −1 for sore throat,
+1 for night sweats, +1 for myalgia, +1
for sputum, +2 for respiratory rate >25,
+2 for temperature >37.7°C
3%1819 (ED)Diehr, 19842
250 (<0.001)0.68 (0.62 to 0.73)0.58 (0.45 to
0.70)
0.75 (0.71 to
0.79)
–3.539, +0.884 for cough, +0.681 for
fever, +0.464 for crackles, +0.030 for
5.0 (pretest probability of pneumonia§)
16%225 (ED)Singal, 198912
832 (<0.001)0.65 (0.59 to 0.70)0.63 (0.50 to
0.75)
0.82 (0.78 to
0.86)
–1.705, +0.494 for temperature
>37.7°C, +0.428 for pulse >100
beats/min, +0.658 for rales, +0.638 for
decreased breath sounds, +0.691 for
absence of asthma
5%1134 (ED)Heckerling, 19906
1890 (<0.001)0.65 (0.60 to 0.70)0.49 (0.37 to
0.62)
—+ 4.7 for fever (reported by patient)
with duration of illness of >1 week,
–4.5 for coryza, –2.1 for sore throat,
+5.0 for dyspnoea, +8.2 for chest pain,
lateral +0.9 for crackles
5%402 (OHD)Melbye, 19929
394 (<0.001)0.55 (0.50 to 0.61)0.62 (0.50 to
0.75)
0.76 (NA)–2.74, +1.02 for dry cough, +1.78 for
diarrhoea, +1.13 for temperature
≥38°C
13%246 (GP)Hopstaken, 20037
(signs and
symptoms)
334 (<0.001)0.71 (0.66 to 0.76)0.69 (0.58 to
0.80)
0.80 (NA)–4.15, +0.91 for dry cough, +1.01 for
diarrhoea, +0.64 for temperature
≥38°C, +2.78 for C reactive protein
≥20 mg/L
13%246 (GP)Hopstaken, 20037
(signs,
symptoms, CRP)
NA=not available.
*Setting: ED=emergency department, OHD=out of hours department, GP=general practice.
†In Graffelman.13
‡ Hosmer and Lemeshow test. After adjustment of intercept (to correct for difference in prevalence between derivation and validation cohorts), calibration remained
poor (P<0.01).
§Pre-test probability of pneumonia was proportion of patients with pneumonia (5%) in our dataset.
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Table 3| Reclassification: comparison of diagnostic risk for presence of pneumonia by diagnostic model with and without addition of
measurement of C reactive protein (CRP). Figures are numbers of patients (%)
Risk according to “symptoms and signs” model plus CRP >30 mg/LRisk
according to Patients without pneumoniaPatients with pneumonia
“symptoms
and signs”
model
(without CRP) Total>20%2.5-20%<2.5%Total>20%2.5-20%<2.5%
6540 (0)86 (13)568 (87)110 (0)7 (64)4 (36)*<2.5%
198764 (3)966 (49)957 (48)10522 (21)56 (53)*27 (26)2.5-20%
3927 (69)12 (31)0 (0)2419 (79)*5 (21)0 (0)>20%
26809110641525140416831Total
*Patients classified in agreement according to model with and without CRP >30 mg/L. Of all patients with pneumonia 29 (22+7+0) are reclassified to higher risk
groups, and 32 (27+5) to lower risk groups. For patients without pneumonia this is 150 (86+64) and 969 (957+12), respectively. Reclassification improvement is
−2% among patients with pneumonia (29-32 of 140) and 30% among patients without pneumonia (957-150 of 2680), resulting in net reclassification improvement
of −2+30=28% (95% CI 0.17 to 0.40).
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Table 4| Diagnostic risk classification of pneumonia by simplified diagnostic score in 2820 patients with acute cough
Symptoms and signs + CRP >30 mg/L*
Score (risk category) No with pneumonia (observed prevalence)No of patients (% of 2820)
4 (0.7)572 (20.3)0 (low)
73 (3.8)1902 (67.4)1-2 (intermediate)
63 (18.2)346 (12.3)≥3 (high)
140 (0.05)2820 (100)All
*Score: 1×absence of runny nose+1×breathlessness+1×crackles+1×diminished vesicular breathing+1×raised pulse (>100/min)+1×fever (temperature >37.8°C)
1×raised CRP (>30 mg/L).
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Figures
Fig 1 Recruitment and flow of participants with acute cough to determine diagnosis of pneumonia
Fig 2 ROC curves of symptoms and signs and added value CRP and procalcitonin (continuous results). Linear predictors
for estimated risk of pneumonia: symptoms and signs=1/(1+exp−(−3.984+0.446×breathlessness+0.698×absence of runny
nose+0.596×diminished vesicular breathing+1.404×crackles+0.961×tachycardia+0.980×temperature >37.8°C)); symptoms
signs and CRP=1/(1+exp−(−4.270+0.446×breathlessness+0.698×absence of runny nose+0.596×diminished vesicular
breathing+1.404×crackles+0.961×tachycardia+0.980×temperature >37.8°C+0.130×(CRP/10))); symptoms signs and
PCT=1/(1+exp−(−4.023+0.446×breathlessness+0.698×absence of runny nose+0.596×diminished vesicular
breathing+1.404×crackles+0.961×tachycardia+0.980×temperature >37.8+0.160×(PCT×10)))
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